Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Roddie · SciRah

Researcher profile · Semantic Scholar

C. Roddie

Share profile

C. Roddie — researcher profile on SciRah

h-index: 33
Works: 184
Citations: 5,550

Most-cited papers

Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations.
K. Rejeski, M. Subklewe, M. Aljurf, E. Bachy +33 more
2023Blood346 citations Open access
Semantic Scholar
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
C. Roddie, Karamjeet S Sandhu, E. Tholouli, Aaron C. Logan +27 more
2024New England Journal of Medicine173 citations Open access
Semantic Scholar
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
C. Roddie, Lorna Neill, W. Osborne, S. Iyengar +15 more
2023Blood Advances142 citations Open access
Semantic Scholar
CAR-T cell manufacturing landscape—Lessons from the past decade and considerations for early clinical development
J. Dias, John Garcia, G. Agliardi, C. Roddie
2024Molecular Therapy: Methods & Clinical Development100 citations Open access
Semantic Scholar
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
C. Roddie, L. Lekakis, M. Marzolini, A. Ramakrishnan +23 more
2023Blood91 citations Open access
Semantic Scholar
Accelerating and optimising CAR T-cell manufacture to deliver better patient products.
G. Agliardi, J. Dias, Alexandros Rampotas, John Garcia +1 more
2024The Lancet Haematology64 citations
Semantic Scholar
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.
Charlotte E. Graham, Roser Velasco, Ana Alarcon Tomas, Orla P. Stewart +14 more
2025The Lancet Oncology61 citations Open access
Semantic Scholar
CAR-T cell therapy embarks on autoimmune disease
A. Rampotas, Johanna Richter, D. Isenberg, C. Roddie
2024Bone Marrow Transplantation53 citations Open access
Semantic Scholar
The present and future for CAR-T cell therapy in adult B-cell ALL.
C. Roddie, Alexandros Rampotas
2024Blood46 citations
Semantic Scholar
Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
G. Iacoboni, J. Iraola-Truchuelo, M. O'Reilly, Víctor Navarro +30 more
2024HemaSphere41 citations Open access
Semantic Scholar
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Gustavo de Oliveira Canedo, C. Roddie, P. Amrolia
2024Blood Advances40 citations Open access
Semantic Scholar
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
M. O'Reilly, William Wilson, D. Burns, A. Kuhnl +20 more
2024HemaSphere31 citations Open access
Semantic Scholar
Outcome and feasibility of radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T in the UK
A. Kuhnl, C. Roddie, A. Kirkwood, S. Chaganti +24 more
2024British Journal of Haematology29 citations Open access
Semantic Scholar
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
Vedika Mehra, G. Agliardi, Juliana Dias Alves Pinto, Manar S Shafat +9 more
2023Journal for ImmunoTherapy of Cancer28 citations Open access
Semantic Scholar
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Frederick W Vonberg, Imran Malik, M. O'Reilly, H. Hyare +2 more
2025Journal of Neurology Neurosurgery & Psychiatry21 citations
Semantic Scholar
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy
A. Hwang, Vedika Mehra, Jyoti Chhetri, Samira Ali +2 more
2024Cancers21 citations Open access
Semantic Scholar
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
C. Roddie, Karamjeet S. Sandhu, E. Tholouli, P. Shaughnessy +15 more
2023Journal of Clinical Oncology20 citations
Semantic Scholar
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
Macarena Oporto Espuelas, Saskia Burridge, A. Kirkwood, Denise Bonney +32 more
2024Blood Cancer Journal17 citations Open access
Semantic Scholar
Improved outcomes of large B‐cell lymphoma patients treated with CD19 CAR T in the UK over time
S. Boyle, C. Roddie, M. O'Reilly, T. Menne +21 more
2023British Journal of Haematology16 citations Open access
Semantic Scholar
Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
Alexandros Rampotas, Z. Wong, Isaac Gannon, Camélia Benlabiod +14 more
2024Blood14 citations
Semantic Scholar
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
M. O'Reilly, Lorna Neill, Simon M. Collin, N. Stone +8 more
2024HemaSphere14 citations Open access
Semantic Scholar
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
Guillermo Ortí, G. Dachy, Charlotte E. Graham, Z. Perić +14 more
2025Bone Marrow Transplantation12 citations
Semantic Scholar
Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study
C. Roddie, Karamjeet S. Sandhu, E. Tholouli, P. Shaughnessy +30 more
2023Blood12 citations Open access
Semantic Scholar
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
Tim Meyer, R. Finn, M. Borad, A. Mahipal +30 more
2025Journal of Hepatology11 citations Open access
Semantic Scholar
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
C. Roddie, J. Dias, M. O'Reilly, M. Abbasian +22 more
2025Blood11 citations Open access
Semantic Scholar
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature.
K. P. Cheok, A. Farrow, D. Springell, M. O'Reilly +3 more
2024Lancet. Infectious Diseases (Print)10 citations
Semantic Scholar
Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells
G. Iacoboni, M. Sánchez-Salinas, K. Rejeski, A. Martín-López +20 more
2024HemaSphere9 citations Open access
Semantic Scholar
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy
G. Iacoboni, K. Rejeski, Víctor Navarro, T. van Meerten +20 more
2025Leukemia8 citations Open access
Semantic Scholar
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
C. Bourlon, C. Roddie, T. Menne, J. Norman +19 more
2024Haematologica8 citations Open access
Semantic Scholar
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Elias Jabbour, Karamjeet S Sandhu, P. Shaughnessy, Aaron C. Logan +16 more
2026Haematologica7 citations Open access
Semantic Scholar
Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies
I. Tsagkaraki, Isaac Gannon, A. Rampotas, Devika Singh +3 more
2026Cancers6 citations Open access
Semantic Scholar
Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
E. Jabbour, Jae H. Park, P. Shaughnessy, Aaron C. Logan +10 more
2024Blood6 citations
Semantic Scholar
Release Assays and Potency Assays for CAR T-Cell Interventions.
J. Dias, Amaia Cadinanos-Garai, C. Roddie
2023Advances in Experimental Medicine and Biology6 citations
Semantic Scholar
Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)
C. Roddie, E. Tholouli, P. Shaughnessy, E. Jabbour +22 more
2023Blood5 citations Open access
Semantic Scholar
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
A. Rampotas, Z. Wong, Isaac Gannon, Charlotte K. Brierley +23 more
2026bioRxiv4 citations Open access
Semantic Scholar
Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)
C. Roddie, Jae H. Park, E. Tholouli, Karamjeet S. Sandhu +13 more
2025Blood4 citations
Semantic Scholar
Single‐centre experience of implementing physiotherapist‐led prehabilitation for chimeric antigen receptor T cell therapy
O. McCourt, P. Maciocia, C. Roddie, A. Hwang +5 more
2024eJHaem4 citations Open access
Semantic Scholar
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
M. O'Reilly, William Wilson, B. Maybury, A. Kuhnl +25 more
2026British Journal of Haematology3 citations Open access
Semantic Scholar
Clonal evolution and the risk of secondary myeloid neoplasia following chimeric antigen receptor T-cell therapy
F. Sillito, Alexandros Rampotas, K. Cheok, Sabine Pomplun +6 more
2025Haematologica3 citations Open access
Semantic Scholar
CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma
Daniel H. Chen, M. O'Reilly, K. Cheok, R. Low +6 more
2024eJHaem3 citations Open access
Semantic Scholar
Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence
L. Lee, W. Lim, Catriona E Mactier, Juliana Dias Alves Pinto +19 more
2023Blood3 citations Open access
Semantic Scholar
Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK
A. Kuhnl, A. Kirkwood, M. Northend, Caroline Besley +44 more
2025HemaSphere2 citations Open access
Semantic Scholar
Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel)
Elias Jabbour, Jae H. Park, P. Shaughnessy, Aaron C. Logan +9 more
2025Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar
Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
B. Shah, D. Yallop, E. Jabbour, P. Barba +12 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
A. Kuhnl, A. Kirkwood, C. Roddie, C. Besley +33 more
2024Blood2 citations
Semantic Scholar
Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
C. Roddie, Jae H. Park, P. Shaughnessy, Aaron C. Logan +9 more
2024Blood2 citations
Semantic Scholar
Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
G. Iacoboni, K. Rejeski, Víctor Navarro Garcés, T. van Meerten +19 more
2024Blood2 citations
Semantic Scholar
Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.
L. Nastoupil, M. Kamdar, J. Chavez, H. Ghesquières +16 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
CAR T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations
A. Hwang, A. Kirkwood, P. Hardefeldt, Mathew Amrith +8 more
2026Haematologica1 citations Open access
Semantic Scholar
To c or not to c-KIT?: High toxicity and modest efficacy in CD117-directed CAR T cell therapy.
Isaac Gannon, C. Roddie, Alex Rampotas
2025Molecular Therapy1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Chaganti×13
Invite
S. Chaganti — researcher profile on SciRah
M. O'Reilly×12
Invite
M. O'Reilly — researcher profile on SciRah
P. Barba×11
Invite
P. Barba — researcher profile on SciRah
A. Kuhnl×11
Invite
A. Kuhnl — researcher profile on SciRah

×9

Invite

E. Tholouli — researcher profile on SciRah

Wolfram Brugger×9

Invite

Wolfram Brugger — researcher profile on SciRah

Invite

D. DeAngelo — researcher profile on SciRah

Aaron C. Logan×8

Invite

Aaron C. Logan — researcher profile on SciRah

P. Shaughnessy×8

Invite

P. Shaughnessy — researcher profile on SciRah

Invite

B. Shah — researcher profile on SciRah

Invite

M. Pule — researcher profile on SciRah

Invite

C. Besley — researcher profile on SciRah